Pathophysiology of systemic sclerosis (scleroderma)
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Systemic sclerosis (scleroderma) is an autoimmune‐triggered chronic fibrosing disease that affects the skin and many other organs. Its pathophysiology is complex and involves an early endothelial damage, an inflammatory infiltrate and a resulting fibrotic reaction. Based on a predisposing genetic background, an altered balance of the acquired and the innate immune system leads to the release of many cytokines and chemokines as well as autoantibodies, which induce the activation of fibroblasts with the formation of myofibroblasts and the deposition of a stiff and rigid connective tissue. A curative treatment is still not available but remarkable progress has been made in the management of organ complications. In addition, several breakthroughs in the pathophysiology have led to new therapeutic concepts. Based on these, many new compounds have been developed during the last years, which target these different pathways and offer specific therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“noglycans, tenascin and fibronectin in the ECM of the affected tissues.(2,5,6,91) The ECM of SSc patients contains increased amounts of collagen type I, III, V, and VI, as well as fibronectin and proteoglycans”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
Gabbiani, G., Ryan, G. B., & Majno, G. (1971) · Experientia · doi:10.1007/bf02147594 · Cited by 1,485
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940
Neutrophil-derived cytokines: facts beyond expression
Tecchio, C., Micheletti, A., & Cassatella, M. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00508 · Cited by 699
Khalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505
Cross Talk among TGF- Signaling Pathways, Integrins, and the Extracellular Matrix
Munger, J. S., & Sheppard, D. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005017 · Cited by 372 · cited 1×
“mediated tension also promotes the release of active TGFβ from the ECM where it is stored in a latent, inactive form.(90)”
BackgroundMarangoni, R. G., Korman, B. D., Wei, J., Wood, T. A., Graham, L. V., Whitfield, M. L., Scherer, P. E., Tourtellotte, W. G., & Varga, J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38990 · Cited by 337
Manetti, M., Romano, E., Rosa, I., Guiducci, S., Bellando-Randone, S., De Paulis, A., Ibba-Manneschi, L., & Matucci-Cerinic, M. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210229 · Cited by 278
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
Lagares, D., Santos, A., Grasberger, P. E., Liu, F., Probst, C. K., Rahimi, R. A., Sakai, N., Kuehl, T., Ryan, J., Bhola, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3765 · Cited by 246 · cited 3×
“Similarly, in SSc myofibroblasts, the mechanotransduction pathway causes mitochondrial priming (a lowered threshold for apoptosis) by increased amounts of the pro-apoptotic protein BIM.(70) As a result, the SSc myofibroblasts depend on the upregulation of anti-apoptotic BCL-XL (that inhibits BIM activation) to survive.”
BackgroundInfluentialInterleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts
Oriente, A., Fedarko, N. S., Pacocha, S. E., Huang, S.-K., Lichtenstein, L. M., & Essayan, D. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35380-7 · Cited by 230 · cited 1×
“inhibiting the synthesis of collagenases like metalloproteinase (MMP)1 and MMP3 and enhancing tissue inhibitor of metalloproteinase (TIMP)-1.(31) TGFβ is involved in several signaling cascades that promote inflammatory and “fibrogenic” effects in SSc patients.”
BackgroundIntegrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma
Gerber, E. E., Gallo, E. M., Fontana, S. C., Davis, E. C., Wigley, F. M., Huso, D. L., & Dietz, H. C. (2013) · Nature · doi:10.1038/nature12614 · Cited by 190 · cited 1×
“High expression of ICAM1 is seen in SSc lesions; ICAM1 can facilitate invasion of T cells that are attracted by a local increase in TGFβ levels.(47,48) Type 2 T helper (Th2) cells are considered to play a key role in SSc.”
BackgroundYamakage, A., Kikuchi, K., Smith, E. A., LeRoy, E. C., & Trojanowska, M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1227 · Cited by 184
François, A., Chatelus, E., Wachsmann, D., Sibilia, J., Bahram, S., Alsaleh, G., & Gottenberg, J.-E. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4352 · Cited by 149
Are mast cells instrumental for fibrotic diseases?
Overed-Sayer, C., Rapley, L., Mustelin, T., & Clarke, D. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00174 · Cited by 105
Nikitorowicz-Buniak, J., Denton, C. P., Abraham, D., & Stratton, R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134092 · Cited by 73
Horikawa, M., Hasegawa, M., Komura, K., Hayakawa, I., Yanaba, K., Matsushita, T., Takehara, K., & Sato, S. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23767.x · Cited by 72
PAI1 mediates fibroblast-mast cell interactions in skin fibrosis
Pincha, N., Hajam, E. Y., Badarinath, K., Batta, S. P. R., Masudi, T., Dey, R., Andreasen, P., Kawakami, T., Samuel, R., George, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99088 · Cited by 70 · cited 2×
“Mast cells are attracted into fibrotic lesions by local PAI (plasminogen activator inhibitor) signaling stemming from epidermal keratinocytes.(42) Their infiltration can precede the first pathological”
BackgroundJafarinejad‐Farsangi, S., Farazmand, A., Gharibdoost, F., Karimizadeh, E., Noorbakhsh, F., Faridani, H., Mahmoudi, M., & Jamshidi, A. R. (2016) · International Journal of Dermatology · doi:10.1111/ijd.13308 · Cited by 39 · cited 2×
“In SSc cells, miRNA21 expression is increased and binds to the mRNA of the pro-apoptotic BAX.74 This is supported by an earlier study, which stated that SSc myofibroblasts have reduced levels of the pro-apoptotic BAX compared to control myofibroblasts.68 This could increase the apoptotic threshold in SSc myofibroblast…”
BackgroundSamuel, G. H., Lenna, S., Bujor, A. M., Lafyatis, R., & Trojanowska, M. (2012) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2012.06.001 · Cited by 22 · cited 1×
“TGFβ signaling has been described to lower the Acid Sphingomyelinase (ASMase) amount in normal fibroblasts.(73) This is interesting because ASMase is a major sphingolipid enzyme that is downregulated in SSc fibroblasts and plays a significant role in Fas-mediated apoptosis”
Background
Metadata
- Authors
- Rosendahl, A., Schönborn, K., & Krieg, T.
- Venue
- The Kaohsiung Journal of Medical Sciences
- Publisher
- Wiley
- Published
- 2022-03
- Volume
- 38
- Issue
- 3
- Pages
- 187-195
- ISSN
- 1607-551X (ISSN-L)
- 2410-8650
- OpenAlex
- W4214815303
- Cited by
- 160
- References
- 20
- FWCI
- 18.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.